A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-21. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Low-level waste (LLW) is generated from hospitals and industry, as well as the nuclear fuel cycle. Low-level wastes include paper, rags, tools, clothing, filters, and other materials which contain small amounts of mostly short-lived radioactivity. Materials that originate from any region of an active area are commonly designated as LLW as a precautionary measure even if there is only a remote possibility of being contaminated with radioactive materials. Such LLW typically exhibits no higher radioactivity than one would expect from the same material disposed of in a non-active area, such as a normal office block. Example LLW includes wiping rags, mops, medical tubes, laboratory animal carcasses, and more. LLW makes up 94% of all radioactive waste volume in the UK. Most of it is disposed of in Cumbria, first in landfill style trenches, and now using grouted metal containers that are stacked in concrete vaults. A new site in the north of Scotland is the Dounreay site which is prepared to withstand a 4m tsunami.[1] Some high-activity LLW requires shielding during handling and transport but most LLW is suitable for shallow land burial. To reduce its volume, it is often compacted or incinerated before disposal. Low-level waste is divided into four classes: class A, class B, class C, and Greater Than Class C (GTCC).
=== Wartime 1939–1945 === In 1939, a collection of 16 poems and seven of the 20 short stories published by Thomas in magazines since 1934, appeared as The Map of Love. Ten stories in his next book, Portrait of the Artist as a Young Dog (1940), were based less on lavish fantasy than those in The Map of Love and more on real-life romances featuring himself in Wales. Sales of both books were poor, resulting in Thomas living on meagre fees from writing and reviewing. At this time he borrowed heavily from friends and acquaintances. Hounded by creditors, Thomas and his family left Laugharne in July 1940 and moved to the home of critic John Davenport in Marshfield near Chippenham in Gloucestershire. There Thomas collaborated with Davenport on the satire The Death of the King's Canary, though due to fears of libel the work was not published until 1976. At the outset of the Second World War, worried about conscription, Thomas unsuccessfully sought employment in a reserved occupation with the Ministry of Information. However, an "unreliable lung", as he described his chronic condition—coughing sometimes confined him to bed, and he had a history of bringing up blood and mucus—proved to be the grounds for the military authorities to allocate him a C3 category medical exemption which meant that he would be among the last to be called up for service.
Focke-Wulf A 3 Focke-Wulf A 4 Focke-Wulf A 5 Focke-Wulf A 6 Focke-Wulf A 7 Focke-Wulf A 16 – light transport aircraft, 1924. First design built by Focke-Wulf. Focke-Wulf A 17 Möwe (Gull) – 8-passenger airliner, 1927. Focke-Wulf A 20 Habicht (Hawk) – 4-passenger feederliner, 1927. Focke-Wulf A 21 Photomöwe – aerial photography version of A 17, 1929. Focke-Wulf A 26 – engine testbed Focke-Wulf A 28 – A 20 with Bristol Titan engine Focke-Wulf A 29 – production version of A 17, 1929. Focke-Wulf A 32 Bussard (Buzzard) – airliner, 1930. Focke-Wulf A 33 Sperber (Sparrowhawk) – 3-passenger airliner, 1930. Focke-Wulf A 36 Mastgans (Mast Goose) – mail plane, 1931. Focke-Wulf A 38 Möwe (Gull) – 10-passenger airliner, 1931. Focke-Wulf F 19 Ente (Duck) – experimental civil utility aircraft, 1927. Focke-Wulf GL 18 – light transport aircraft developed from the A 16, 1926. Focke-Wulf GL 22 – revised GL 18, 1927. Focke-Wulf K 23 Buchfink (Chaffinch) – two-seat reconnaissance aircraft, 1928. Focke-Wulf AL 101 D Albatros Focke-Wulf S 1 – trainer, 1925. Focke-Wulf S 2 – two-seat trainer, 1928. Focke-Wulf S 24 Kiebitz (Lapwing) – two-seat sports biplane, 1928. Focke-Wulf S 39 – two-seat reconnaissance parasol monoplane, 1931-1932. Focke-Wulf W 4 – reconnaissance floatplane, 1927. Focke-Wulf W 7 – maritime patrol biplane, 1932.
Sources: en.wikipedia.org
== Clinical significance == GSH is a key cellular antioxidant and plays a major role in the phase 2 metabolic clearance of electrophilic xenobiotics. The importance of the GSH pathway and enzymes that affect this delicate balance is gaining an increased level of attention in recent years. Although glutathione reductase has been an attractive target for many pharmaceuticals, there have been no successful glutathione reductase related therapeutic compounds created to date. In particular, glutathione reductase appears to be a good target for anti-malarials, as the glutathione reductase of the malaria parasite Plasmodium falciparum has a significantly different protein fold than that of mammalian glutathione reductase. By designing drugs specific to p. falciparum it may be possible to selectively induce oxidative stress in the parasite, while not affecting the host. There are two main classes of GR targeting compounds:
Cligosiban (INNTooltip International Nonproprietary Name; developmental code names IX-01 and PF-3274167) is an oxytocin receptor antagonist which is or was under development for the treatment of premature ejaculation. It is taken orally. The drug is a small molecule or non-peptide and is a potent, highly selective, and brain-penetrant antagonist of the oxytocin receptor. Cligosiban was originated by Pfizer and is under development by Ixchelsis and Chorus Group. As of December 2019, it is in phase 2 clinical trials. However, another source lists the drug's development as having been discontinued. The drug failed to show effectiveness in a phase 2b trial.
In 1999, the Institute of Medicine published the Safety of Silicone Breast Implants (1999) study that reported no evidence that saline-filled and silicone-gel filled breast implant devices caused systemic health problems; that their use posed no new health or safety risks; and that local complications are "the primary safety issue with silicone breast implants", in distinguishing among routine and local medical complications and systemic health concerns." In 2000, the FDA approved saline breast implant Premarket Approval Applications (PMA) containing the type and rate data of the local medical complications experienced by the breast surgery patients. "Despite complications experienced by some women, the majority of those women still in the Inamed Corporation and Mentor Corporation studies, after three years, reported being satisfied with their implants." The premarket approvals were granted for breast augmentation, for women at least 18 years old, and for women requiring breast reconstruction. In 2006, for the Inamed Corporation and for the Mentor Corporation, the U.S. Food and Drug Administration lifted its restrictions against using silicone-gel breast implants for breast reconstruction and for augmentation mammoplasty. Yet, the approval was conditional upon accepting FDA monitoring, the completion of 10-year-mark studies of the women who already had the breast implants, and the completion of a second, 10-year-mark study of the safety of the breast implants in 40,000 other women.
=== Early 20th century === After the near dissolution of the tribal government of the Cherokee Nation in the 1900s and the death of William Charles Rogers in 1917, the Federal government began to appoint chiefs to the Cherokee Nation in 1919. The service time for each appointed chief was so brief that it became known as "Chief for a Day". Six men fell under this category, the first being Andrew B. Cunningham, who served from November 8 to November 25. In the 1930s, the Franklin D. Roosevelt administration worked to improve conditions by supporting the Indian Reorganization Act of 1934, which encouraged tribes to reconstitute their governments and write constitutions. On August 8, 1938, the tribe convened a general convention in Fairfield, Oklahoma to elect a Chief. They chose J. B. Milam as Principal Chief. President Franklin D. Roosevelt confirmed the election in 1941. W. W. Keeler was appointed chief in 1949. After the U.S. government under President Richard Nixon had adopted a self-determination policy, the nation was able to rebuild its government. The people elected W. W. Keeler as chief. Keeler, who was also the president of Phillips Petroleum, was succeeded by Ross Swimmer. In 1975, the tribe drafted a constitution, under the name Cherokee Nation of Oklahoma, which was ratified on June 26, 1976. In 1985 Wilma Mankiller was elected as the first female chief of the Cherokee Nation.
Sources: en.wikipedia.org
== Prognosis == Twenty-five percent of psychiatric patients with catatonia will have more than one episode throughout their lives. Treatment response for patients with catatonia is 50–70%, with treatment failure being associated with a poor prognosis. Many of these patients will require long-term and continuous mental health care. The prognosis for people with catatonia due to schizophrenia is much worse compared to other causes. In cases of malignant catatonia, the mortality rate is as high as 20%.
==== Reception ==== Critical reception to the super-soldiers was mixed. The A.V. Club was highly critical of the final season and its mythology story, noting that the "new serialized storylines about so-called 'super soldiers'" resulted in a "clumsy mish-mash of" ideas that worked and did not. Not all reviews were negative, however. Den of Geek also named the Super Soldiers among "The Top 10 X-Files Baddies". The site wrote moderately positively of the Super soldiers and applauded the show's continuity, citing their decision to make Billy Miles, a character who appeared in the series' pilot episode, the first super-soldier. However, the review did call them not "as interesting as what came before them". The site awarded the super soldiers a "Coolness" rating of three out of five, an "Impact" rating of three out of five, and a "Creepiness" rating of two out of five.
== Thiyl radicals == Free radicals derived from mercaptans, called thiyl radicals, are commonly invoked to explain reactions in organic chemistry and biochemistry. They have the formula RS• where R is an organic substituent such as alkyl or aryl. They arise from or can be generated by a number of routes, but the principal method is H-atom abstraction from thiols. Another method involves homolysis of organic disulfides. In biology thiyl radicals are responsible for the formation of the deoxyribonucleic acids, building blocks for DNA. This conversion is catalysed by ribonucleotide reductase (see figure). Thiyl intermediates also are produced by the oxidation of glutathione, an antioxidant in biology. Thiyl radicals (sulfur-centred) can transform to carbon-centred radicals via hydrogen atom exchange equilibria. The formation of carbon-centred radicals could lead to protein damage via the formation of C−C bonds or backbone fragmentation. Because of the weakness of the S−H bond, thiols can function as scavengers of free radicals.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.